nach oben

Die Gynäkologie

Erschienen in:

10.01.2017 | Gynäkologische Onkologie | Review

Hormones and risk of breast and gynecological cancer

A systematic review

verfasst von: Dr. med. Susanne Schüler-Toprak, Stephan Seitz, Olaf Ortmann

Erschienen in: Die Gynäkologie | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Breast and gynecological cancers are often hormone dependent. The role of reproductive factors and endogenous hormones in tumorigenesis of these tumors has been investigated in numerous studies. Safety of oral contraception, hormone therapy during perimenopause or postmenopause or fertility treatment is of special interest for the information of women who are planning to use these therapies.

Objective

This article provides an update on the current knowledge on hormones and risk of breast and gynecological cancers.

Material and methods

We performed a systematic search in the Medline literature database through PubMed using the search terms “estrogen”, “testosterone”, “progesterone”, “gestagen”, “progestagen”, “hormone therapy”, “hormone treatment”, “hormonal contraception”, “ovulation induction”, “menopausal” “breast cancer”, “ovarian cancer”, “endometrial cancer” and “cervical cancer”. Articles published between 2010 and may 2016 were included.

Results and conclusion

Reproductive factors influence tumorigenesis of breast, ovarian and endometrial cancers. Oral contraception increases breast cancer risk but is protective against ovarian and endometrial cancers. The influence of ovarian hyperstimulation has been controversially discussed and no clear association with these hormone-dependent tumors has been observed. Hormone therapy in perimenopause and postmenopause and its influence on hormone dependent cancers is highly complex. Combined therapy containing estrogen and progestin (EPT) seems to increase breast cancer risk after use for approximately 5 years whereas estrogen only therapy (ET) does not or to a lesser extent. Hormone therapy increases ovarian cancer risk. Endometrial cancer risk is significantly increased by ET, whereas for EPT no significant effect has been observed. After diagnosis of breast and gynecological cancers hormone therapy is contraindicated as an increased risk of recurrence cannot be ruled out.

Ali AT (2014) Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer 24:384–393PubMedCrossRef

Allen NE, Key TJ, Dossus L et al (2008) Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 15:485–497PubMedPubMedCentralCrossRef

Ameye L, Antoine C, Paesmans M et al (2014) Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas 79:287–291PubMedCrossRef

Anderson GL, Chlebowski RT, Aragaki AK et al (2012) Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol 13:476–486PubMedPubMedCentralCrossRef

Anonymous (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–1727CrossRef

Anonymous (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350:1047–1059CrossRef

Anonymous (2005) The role of testosterone therapy in postmenopausal women: position statement of the North American Menopause Society. Menopause 12:496–511 (quiz 649)CrossRef

Anonymous (2012) Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLOS Med 9:e1001200CrossRef

Anonymous (2012) The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause 19:257–271CrossRef

10.

Anonymous (2015) Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 16:1061–1070CrossRef

11.

Antoine C, Ameye L, Paesmans M et al (2016) Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries. Maturitas 84:81–88PubMedCrossRef

12.

Antoine C, Liebens F, Carly B et al (2007) Safety of hormone therapy after breast cancer: a qualitative systematic review. Hum Reprod 22:616–622PubMedCrossRef

13.

Antoine C, Ameye L, Paesmans M et al (2012) Update of the evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium. Maturitas 72:317–323PubMedCrossRef

14.

Antoine C, Ameye L, Paesmans M et al (2014) Treatment of climacteric symptoms in breast cancer patients: a retrospective study from a medication databank. Maturitas 78:228–232PubMedCrossRef

15.

Appleby P, Beral V, Berrington De Gonzalez A et al (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370:1609–1621PubMedCrossRef

16.

Asante A, Leonard PH, Weaver AL et al (2013) Fertility drug use and the risk of ovarian tumors in infertile women: a case-control study. Fertil Steril 99:2031–2036PubMedPubMedCentralCrossRef

17.

Ayhan A, Taskiran C, Simsek S et al (2006) Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 16:805–808PubMedCrossRef

18.

Bakken K, Fournier A, Lund E et al (2011) Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 128:144–156PubMedCrossRef

19.

Ballard-Barbash R, Friedenreich CM, Courneya KS et al (2012) Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 104:815–840PubMedPubMedCentralCrossRef

20.

Benkhadra K, Mohammed K, Al Nofal A et al (2015) Menopausal hormone therapy and mortality: a systematic review and meta-analysis. J Clin Endocrinol Metab 100:4021–4028PubMedCrossRef

21.

Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427PubMedCrossRef

22.

Beral V, Bull D, Green J et al (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369:1703–1710PubMedCrossRef

23.

Beral V, Reeves G, Bull D et al (2011) Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103:296–305PubMedPubMedCentralCrossRef

24.

Beral V, Gaitskell K, Hermon C et al (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835–1842PubMedCrossRef

25.

Bhaskaran K, Douglas I, Forbes H et al (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 384:755–765PubMedPubMedCentralCrossRef

26.

Biglia N, Bounous VE, Sgro LG et al (2015) Treatment of climacteric symptoms in survivors of gynaecological cancer. Maturitas 82:296–298PubMedCrossRef

27.

Biliatis I, Thomakos N, Rodolakis A et al (2012) Safety of hormone replacement therapy in gynaecological cancer survivors. J Obstet Gynaecol 32:321–325PubMedCrossRef

28.

Bodelon C, Wentzensen N, Schonfeld SJ et al (2013) Hormonal risk factors and invasive epithelial ovarian cancer risk by parity. Br J Cancer 109:769–776PubMedPubMedCentralCrossRef

29.

Bosetti C, Negri E, Franceschi S et al (2001) Relationship between postmenopausal hormone replacement therapy and ovarian cancer. JAMA 285:3089 (author reply 3090)PubMedCrossRef

30.

Brinton LA, Moghissi KS, Scoccia B et al (2005) Ovulation induction and cancer risk. Fertil Steril 83:261–274 (quiz 525–266)PubMedCrossRef

31.

Brinton LA, Key TJ, Kolonel LN et al (2015) Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol 33:2041–2050PubMedPubMedCentralCrossRef

32.

Cancer CGOHFIB (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 13:1141–1151CrossRef

33.

Cancer IaFRO (2005) IARC monographs programme finds combined estrogen-progestogen contraceptives and menopausal therapy are carcinogenic to humans. Press release N° 167. IARC, Lyon

34.

Canchola AJ, Chang ET, Bernstein L et al (2010) Body size and the risk of endometrial cancer by hormone therapy use in postmenopausal women in the California Teachers Study cohort. Cancer Causes Control 21:1407–1416PubMedPubMedCentralCrossRef

35.

Canchola AJ, Chang ET, Bernstein L et al (2010) Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort. Cancer Causes Control 21:2241–2248PubMedPubMedCentralCrossRef

36.

Canchola AJ, Anton-Culver H, Bernstein L et al (2012) Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes Control 23(3):473–485. doi:10.1007/s10552-012-9897-x CrossRef

37.

Canchola AJ, Lacey JV Jr., Bernstein L et al (2015) Dietary patterns and endometrial cancer risk in the California Teachers Study cohort. Cancer Causes Control 26(CCC):627–634PubMedPubMedCentralCrossRef

38.

Chapman JA, Disaia PJ, Osann K et al (1996) Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 175:1195–1200PubMedCrossRef

39.

Chin J, Konje JC, Hickey M (2009) Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. doi:10.1002/14651858.cd007245.pub2 PubMed

40.

Chlebowski RT, Anderson GL (2012) Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst 104:517–527PubMedPubMedCentralCrossRef

41.

Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289:3243–3253PubMedCrossRef

42.

Chlebowski RT, Anderson GL, Gass M et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684–1692PubMedPubMedCentralCrossRef

43.

Chlebowski RT, Anderson GL, Aragaki AK et al (2016) Breast cancer and menopausal hormone therapy by race/ethnicity and body mass index. J Natl Cancer Inst 108(2):djv327PubMedCrossRef

44.

Col NF, Kim JA, Chlebowski RT (2005) Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 7:R535–R540PubMedPubMedCentralCrossRef

45.

Collaborative Group on Epidemiological Studies of Ovarian Cancer (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87303 controls. Lancet 371:303–314CrossRef

46.

Collins JA, Blake JM, Crosignani PG (2005) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11:545–560PubMedCrossRef

47.

Coombs NJ, Cronin KA, Taylor RJ et al (2010) The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control 21:83–90PubMedCrossRef

48.

Cordina-Duverger E, Truong T, Anger A et al (2013) Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLOS ONE 8:e78016PubMedPubMedCentralCrossRef

49.

Creasman WT (2005) Hormone replacement therapy after cancers. Curr Opin Oncol 17:493–499PubMed

50.

Creasman WT, Henderson D, Hinshaw W et al (1986) Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67:326–330PubMed

51.

Crosbie EJ, Zwahlen M, Kitchener HC et al (2010) Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 19:3119–3130PubMedCrossRef

52.

Cummings SR, Ettinger B, Delmas PD et al (2008) The effects of tibolone in older postmenopausal women. N Engl J Med 359:697–708PubMedPubMedCentralCrossRef

53.

Cust AE, Kaaks R, Friedenreich C et al (2007) Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 14:755–767PubMedCrossRef

54.

Davis SR, Moreau M, Kroll R et al (2008) Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 359:2005–2017PubMedCrossRef

55.

Davis SR, Hirschberg AL, Wagner LK et al (2009) The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. J Clin Endocrinol Metab 94:4907–4913PubMedCrossRef

56.

De P, Neutel CI, Olivotto I et al (2010) Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst 102:1489–1495PubMedCrossRef

57.

Delgado-Rodriguez M, Sillero-Arenas M, Rodriguez-Contreras R et al (1991) Oral contraceptives and breast cancer. A meta-analysis. Rev Epidemiol Sante Publique 39:165–181PubMed

58.

Dominick S, Hickey M, Chin J et al (2015) Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. doi:10.1002/14651858.cd007245.pub3 PubMed

59.

Donders G, Neven P, Moegele M et al (2014) Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor((R))) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 145:371–379PubMedPubMedCentralCrossRef

60.

Dor J, Lerner-Geva L, Rabinovici J et al (2002) Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 77:324–327PubMedCrossRef

61.

Dossus L, Allen N, Kaaks R et al (2010) Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 127:442–451PubMed

62.

Dossus L, Rinaldi S, Becker S et al (2010) Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer 17:1007–1019PubMedPubMedCentralCrossRef

63.

Dossus L, Lukanova A, Rinaldi S et al (2013) Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort – a factor analysis. Am J Epidemiol 177:787–799PubMedCrossRef

64.

Eeles RA, Tan S, Wiltshaw E et al (1991) Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302:259–262PubMedPubMedCentralCrossRef

65.

Eeles RA, Morden JP, Gore M et al (2015) Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J Clin Oncol 33:4138–4144PubMedCrossRef

66.

Eliassen AH, Missmer SA, Tworoger SS et al (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98:1406–1415PubMedCrossRef

67.

Ennour-Idrissi K, Maunsell E, Diorio C (2015) Effect of physical activity on sex hormones in women: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res 17:139PubMedPubMedCentralCrossRef

68.

Ereman RR, Prebil LA, Mockus M et al (2010) Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California. BMC Public Health 10:228PubMedPubMedCentralCrossRef

69.

Fahlen M, Fornander T, Johansson H et al (2013) Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 49:52–59PubMedCrossRef

70.

Farhat GN, Walker R, Buist DS et al (2010) Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. J Clin Oncol 28:5140–5146PubMedPubMedCentralCrossRef

71.

Farrell R (2016) ACOG committee opinion no. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 127:e93–96PubMedCrossRef

72.

Fearnley EJ, Marquart L, Spurdle AB et al (2010) Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control 21:2303–2308PubMedCrossRef

73.

Felix AS, Gaudet MM, La Vecchia C et al (2015) Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int J Cancer 136:E410–E422PubMedCrossRef

74.

Formoso G, Perrone E, Maltoni S et al (2012) Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. doi:10.1002/14651858.cd008536.pub2 PubMed

75.

Fortner RT, Schock H, Kaaks R et al (2014) Early pregnancy sex steroids and maternal breast cancer: a nested case-control study. Cancer Res 74:6958–6967PubMedPubMedCentralCrossRef

76.

Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103–111PubMedCrossRef

77.

Fournier A, Fabre A, Mesrine S et al (2008) Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 26:1260–1268PubMedPubMedCentralCrossRef

78.

Fournier A, Mesrine S, Boutron-Ruault MC et al (2009) Estrogen-progestagen menopausal hormone therapy and breast cancer: Does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 27:5138–5143PubMedCrossRef

79.

Friedenreich CM, Biel RK, Lau DC et al (2011) Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 20:2384–2395PubMedCrossRef

80.

Friedenreich CM, Neilson HK, Wang Q et al (2015) Effects of exercise dose on endogenous estrogens in postmenopausal women: a randomized trial. Endocr Relat Cancer 22:863–876PubMedCrossRef

81.

Fu Y, Zhuang Z (2014) Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis. Int J Clin Exp Pathol 7:6419–6429PubMedPubMedCentral

82.

Furness S, Roberts H, Marjoribanks J et al (2012) Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. doi:10.1002/14651858.cd000402.pub4

83.

Garg PP, Kerlikowske K, Subak L et al (1998) Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92:472–479PubMed

84.

Gennari A, Costa M, Puntoni M et al (2015) Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies. Breast Cancer Res Treat 150:405–413PubMedCrossRef

85.

Gizzo S, Di Gangi S, Bertocco A et al (2014) Levonorgestrel intrauterine system in adjuvant tamoxifen treatment: balance of breast risks and endometrial benefits – systematic review of literature. Reprod Sci 21:423–431PubMedCrossRef

86.

Gompel A, Plu-Bureau G (2010) Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Ann N Y Acad Sci 1205:268–276PubMedCrossRef

87.

Gompel A, Santen RJ (2012) Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 15:241–249PubMedCrossRef

88.

Grabrick DM, Hartmann LC, Cerhan JR et al (2000) Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 284:1791–1798PubMedCrossRef

89.

Grady D, Gebretsadik T, Kerlikowske K et al (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85:304–313PubMedCrossRef

90.

Greiser CM, Greiser EM, Doren M (2005) Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update 11:561–573PubMedCrossRef

91.

Greiser CM, Greiser EM, Doren M (2007) Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 13:453–463PubMedCrossRef

92.

Guidozzi F (2013) Estrogen therapy in gynecological cancer survivors. Climacteric 16:611–617PubMedCrossRef

93.

Guidozzi F, Daponte A (1999) Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 86:1013–1018PubMedCrossRef

94.

Haoula ZJ, Walker KF, Powell MC (2011) Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 159:176–179PubMedCrossRef

95.

Hemminki E, Kyyronen P, Pukkala E (2008) Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995–2005. Maturitas 61:299–304PubMedCrossRef

96.

Hentschel S, Heinz J, Schmid-Hopfner S et al (2010) The impact of menopausal hormone therapy on the incidence of different breast cancer types – data from the Cancer Registry Hamburg 1991–2006. Cancer Epidemiol 34:639–643PubMedCrossRef

97.

Holm M, Olsen A, Kroman N et al (2014) Lifestyle influences on the association between pre-diagnostic hormone replacement therapy and breast cancer prognosis – results from The Danish ‘Diet, Cancer and Health’ prospective cohort. Maturitas 79:442–448PubMedCrossRef

98.

Holmberg L, Anderson H (2004) HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet 363:453–455PubMedCrossRef

99.

Holmberg L, Iversen OE, Rudenstam CM et al (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100:475–482PubMedCrossRef

100.

Hulley S, Grady D, Bush T et al (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605–613PubMedCrossRef

101.

Hulley S, Furberg C, Barrett-Connor E et al (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:58–66PubMedCrossRef

102.

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, IaFRO Cancer, World Health Organization (1999) Hormonal contraception and post-menopausal hormonal therapy. WHO, IARC, Lyon

103.

Ibeanu O, Modesitt SC, Ducie J et al (2011) Hormone replacement therapy in gynecologic cancer survivors: why not? Gynecol Oncol 122:447–454PubMedCrossRef

104.

Islami F, Liu Y, Jemal A et al (2015) Breastfeeding and breast cancer risk by receptor status – a systematic review and meta-analysis. Ann Oncol 26:2398–2407PubMedPubMedCentral

105.

James RE, Lukanova A, Dossus L et al (2011) Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res (Phila) 4:1626–1635CrossRef

106.

Jensen A, Jensen A, Sharif H et al (2009) Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. BMJ 338:b249. doi:10.1136/bmj.b249 PubMedPubMedCentralCrossRef

107.

Jung S, Egleston BL, Chandler DW et al (2015) Adolescent endogenous sex hormones and breast density in early adulthood. Breast Cancer Res 17:77PubMedPubMedCentralCrossRef

108.

Kaaks R, Rinaldi S, Key TJ et al (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12:1071–1082PubMedCrossRef

109.

Kabat GC, Kim MY, Woods NF et al (2011) Reproductive and menstrual factors and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. Cancer Causes Control 22:1415–1424PubMedCrossRef

110.

Kabat GC, Kamensky V, Heo M et al (2014) Combined conjugated esterified estrogen plus methyltestosterone supplementation and risk of breast cancer in postmenopausal women. Maturitas 79:70–76PubMedCrossRef

111.

Kahlenborn C, Modugno F, Potter DM et al (2006) Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 81:1290–1302PubMedCrossRef

112.

Karimi-Zarchi M, Dehghani-Firoozabadi R, Tabatabaie A et al (2013) A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation. Clin Exp Obstet Gynecol 40:421–424PubMed

113.

Kashyap S, Moher D, Fung MF et al (2004) Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 103:785–794PubMedCrossRef

114.

Katalinic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107:427–430PubMedCrossRef

115.

Kay CR, Hannaford PC (1988) Breast cancer and the pill – a further report from the Royal College of General Practitioners’ oral contraception study. Br J Cancer 58:675–680PubMedPubMedCentralCrossRef

116.

Kenemans P, Bundred NJ, Foidart JM et al (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 10:135–146PubMedCrossRef

117.

Kerlikowske K, Miglioretti DL, Buist DS et al (2007) Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99:1335–1339PubMedCrossRef

118.

Kerlikowske K, Cook AJ, Buist DS et al (2010) Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol 28:3830–3837PubMedPubMedCentralCrossRef

119.

Kesim MD, Aydin Y, Atis A et al (2008) Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric 11:252–257PubMedCrossRef

120.

Key TJ, Appleby PN, Reeves GK et al (2013) Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 14:1009–1019PubMedCrossRef

121.

Key TJ, Appleby PN, Reeves GK et al (2015) Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: reanalysis of eighteen prospective studies. Steroids 99:49–55PubMedCrossRef

122.

Koskela-Niska V, Pukkala E, Lyytinen H et al (2013) Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer – a population-based case control study from Finland. Int J Cancer 133:1680–1688PubMedCrossRef

123.

Kumle M, Weiderpass E, Braaten T et al (2002) Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish Women’s Lifestyle and Health Cohort Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology 11:1375–1381

124.

Kwan ML, Chen WY, Kroenke CH et al (2012) Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 132:729–739PubMedCrossRef

125.

Lacey JV Jr., Mink PJ, Lubin JH et al (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334–341PubMedCrossRef

126.

Lambe M, Wigertz A, Holmqvist M et al (2010) Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat 121:679–683PubMedCrossRef

127.

Lee RB, Burke TW, Park RC (1990) Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36:189–191PubMedCrossRef

128.

Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92:2049–2058PubMedPubMedCentralCrossRef

129.

Leidenberger F, Strowitzki T, Ortmann O (2014) Klinische Endokrinologie für Frauenärzte. Springer, HeidelbergCrossRef

130.

Leitzmann MF, Koebnick C, Danforth KN et al (2009) Body mass index and risk of ovarian cancer. Cancer 115:812–822PubMedPubMedCentralCrossRef

131.

Lerner-Geva L, Geva E, Lessing JB et al (2003) The possible association between in vitro fertilization treatments and cancer development. Int J Gynecol Cancer 13:23–27PubMedCrossRef

132.

Lethaby A, Farquhar C, Sarkis A et al (2000) Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev. doi:10.1002/14651858.cd000402

133.

Levgur M (2004) Estrogen and combined hormone therapy for women after genital malignancies: a review. J Reprod Med 49:837–848PubMed

134.

Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16:2773–2780PubMedCrossRef

135.

Li CI, Malone KE, Porter PL et al (2008) Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev 17:43–50PubMedCrossRef

136.

Li D, Ding CY, Qiu LH (2015) Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol 139:355–362PubMedCrossRef

137.

Li LL, Zhou J, Qian XJ et al (2013) Meta-analysis on the possible association between in vitro fertilization and cancer risk. Int J Gynecol Cancer 23:16–24PubMedCrossRef

138.

Liu Z, Zhang TT, Zhao JJ et al (2015) The association between overweight, obesity and ovarian cancer: a meta-analysis. Jpn J Clin Oncol 45:1107–1115PubMedCrossRef

139.

Longatto-Filho A, Hammes LS, Sarian LO et al (2011) Hormonal contraceptives and the length of their use are not independent risk factors for high-risk HPV infections or high-grade CIN. Gynecol Obstet Invest 71:93–103PubMedCrossRef

140.

Lu L, Risch H, Irwin ML et al (2011) Long-term overweight and weight gain in early adulthood in association with risk of endometrial cancer. Int J Cancer 129:1237–1243PubMedPubMedCentralCrossRef

141.

Luhn P, Dallal CM, Weiss JM et al (2013) Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 22:1304–1312PubMedCrossRef

142.

Lumsden MA, Davies M, Sarri G (2016) Diagnosis and Management of Menopause: the National Institute of Health and Care Excellence (NICE) Guideline. JAMA Intern Med 176(8):1205. doi:10.1001/jamainternmed.2016.2761 PubMedCrossRef

143.

Luo J, Cochrane BB, Wactawski-Wende J et al (2013) Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast. Breast Cancer Res Treat 137:915–925PubMedCrossRef

144.

Lupo M, Dains JE, Madsen LT (2015) Hormone replacement therapy: an increased risk of recurrence and mortality for breast cancer patients? J Adv Pract Oncol 6:322–330PubMedPubMedCentral

145.

Lurie G, Thompson P, Mcduffie KE et al (2007) Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol 109:597–607PubMedCrossRef

146.

Mahdavi A, Mahdavi A, Pejovic T et al (2006) Induction of ovulation and ovarian cancer: a critical review of the literature. Fertil Steril 85:819–826PubMedCrossRef

147.

Manley K, Edey K, Braybrooke J et al (2012) Hormone replacement therapy after endometrial cancer. Menopause Int 18:134–138PubMed

148.

Mariani L, Gadducci A, Vizza E et al (2013) Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy. Gynecol Endocrinol 29:25–29PubMedCrossRef

149.

Marks M, Gravitt PE, Gupta SB et al (2011) The association of hormonal contraceptive use and HPV prevalence. Int J Cancer 128:2962–2970PubMedCrossRef

150.

Marshall SF, Clarke CA, Deapen D et al (2010) Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res 12:R4PubMedPubMedCentralCrossRef

151.

Mascarenhas C, Lambe M, Bellocco R et al (2006) Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 119:2907–2915PubMedCrossRef

152.

Mazzarello S, Hutton B, Ibrahim MF et al (2015) Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Res Treat 152:1–8PubMedCrossRef

153.

Michaelson-Cohen R, Beller U (2009) Managing menopausal symptoms after gynecological cancer. Curr Opin Oncol 21:407–411PubMedCrossRef

154.

Michels KB (2012) The rise and fall of breast cancer rates. BMJ 344:d8003PubMedCrossRef

155.

Morch LS, Lokkegaard E, Andreasen AH et al (2009) Hormone therapy and ovarian cancer. JAMA 302:298–305PubMedCrossRef

156.

Mueck AO, Seeger H, Rabe T (2010) Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer 17:R263–R271PubMedCrossRef

157.

Nachtigall L, Casson P, Lucas J et al (2011) Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol 27:39–48PubMedCrossRef

158.

Negri E, Tzonou A, Beral V et al (1999) Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer 80:848–851PubMedCrossRef

159.

Nelson HD, Humphrey LL, Nygren P et al (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288:872–881PubMedCrossRef

160.

Ness RB, Cramer DW, Goodman MT et al (2002) Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 155:217–224PubMedCrossRef

161.

Neuhouser ML, Aragaki AK, Prentice RL et al (2015) Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the Women’s Health Initiative randomized clinical trials. JAMA Oncol 1:611–621PubMedPubMedCentralCrossRef

162.

Ni XJ, Xia TS, Zhao YC et al (2012) Postmenopausal hormone therapy is associated with in situ breast cancer risk. Asian Pac J Cancer Prev 13:3917–3925PubMedCrossRef

163.

Norman SA, Weber AL, Localio AR et al (2010) Hormone therapy and fatal breast cancer. Pharmacoepidemiol Drug Saf 19:440–447PubMedPubMedCentral

164.

Olsen CM, Nagle CM, Whiteman DC et al (2013) Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer 20:251–262PubMedCrossRef

165.

Orbo A, Vereide A, Arnes M et al (2014) Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG 121:477–486PubMedCrossRef

166.

Ortmann O, König K (2005) Hormontherapie im Klimakterium und in der Postmenopause. Dtsch Arztebl 102:144–147

167.

Ortmann O, Doren M, Windler E (2011) Hormone therapy in perimenopause and postmenopause (HT). Interdisciplinary S3 Guideline, Association of the Scientific Medical Societies in Germany AWMF 015/062-short version. Arch Gynecol Obstet 284:343–355PubMedPubMedCentralCrossRef

168.

Pearce CL, Chung K, Pike MC et al (2009) Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 115:531–539PubMedPubMedCentralCrossRef

169.

Pelucchi C, Levi F, La Vecchia C (2010) The rise and fall in menopausal hormone therapy and breast cancer incidence. Breast 19:198–201PubMedCrossRef

170.

Pergialiotis V, Pitsouni E, Prodromidou A et al (2016) Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause 23:335–342PubMedCrossRef

171.

Prentice RL, Manson JE, Langer RD et al (2009) Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 170:12–23PubMedPubMedCentralCrossRef

172.

Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674PubMedCrossRef

173.

Reeves GK, Pirie K, Beral V et al (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335:1134PubMedPubMedCentralCrossRef

174.

Reeves GK, Pirie K, Green J et al (2012) Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer 131:930–937PubMedCrossRef

175.

Riman T, Dickman PW, Nilsson S et al (2002) Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94:497–504PubMedCrossRef

176.

Rinaldi S, Dossus L, Lukanova A et al (2007) Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev 16:23–29PubMedCrossRef

177.

Risch HA (2002) Hormone replacement therapy and the risk of ovarian cancer. Gynecol Oncol 86:115–117PubMedCrossRef

178.

Ritte R, Lukanova A, Berrino F et al (2012) Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res 14:R76PubMedPubMedCentralCrossRef

179.

Robbins AS, Clarke CA (2007) Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 25:3437–3439PubMedCrossRef

180.

Roberts H, Hickey M, Lethaby A (2014) Hormone therapy in postmenopausal women and risk of endometrial hyperplasia: a Cochrane review summary. Maturitas 77:4–6PubMedCrossRef

181.

Rodriguez C, Patel AV, Calle EE et al (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285:1460–1465PubMedCrossRef

182.

Romieu I, Berlin JA, Colditz G (1990) Oral contraceptives and breast cancer. Review and meta-analysis. Cancer 66:2253–2263PubMedCrossRef

183.

Rosato V, Zucchetto A, Bosetti C et al (2011) Metabolic syndrome and endometrial cancer risk. Ann Oncol 22:884–889PubMedCrossRef

184.

Rose DP, Vona-Davis L (2010) Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 66:33–38PubMedCrossRef

185.

Rosenberg L, Palmer JR, Zauber AG et al (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139:654–661PubMed

186.

Rossing MA, Daling JR, Weiss NS et al (1994) Ovarian tumors in a cohort of infertile women. N Engl J Med 331:771–776PubMedCrossRef

187.

Rossing MA, Cushing-Haugen KL, Wicklund KG et al (2007) Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 16:2548–2556PubMedCrossRef

188.

Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRef

189.

Rushton L, Jones DR (1992) Oral contraceptive use and breast cancer risk: a meta-analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use. Br J Obstet Gynaecol 99:239–246PubMedCrossRef

190.

Rusner C, Bandemer-Greulich U, Engel J et al (2012) Population-based hormone receptor-specific incidence trends of breast cancer in Germany. Maturitas 73:152–157PubMedCrossRef

191.

Salagame U, Banks E, Sitas F et al (2016) Menopausal hormone therapy use and breast cancer risk in Australia: findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study. Int J Cancer 138:1905–1914PubMedCrossRef

192.

Samson M, Porter N, Orekoya O et al (2016) Progestin and breast cancer risk: a systematic review. Breast Cancer Res Treat 155:3–12PubMedCrossRef

193.

Saso S, Louis LS, Doctor F et al (2015) Does fertility treatment increase the risk of uterine cancer? A meta-analysis. Eur J Obstet Gynecol Reprod Biol 195:52–60PubMedCrossRef

194.

Saxena T, Lee E, Henderson KD et al (2010) Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev 19:2366–2378PubMedPubMedCentralCrossRef

195.

Schairer C, Fuhrman BJ, Boyd-Morin J et al (2016) Quantifying the role of circulating unconjugated estradiol in mediating the Body Mass Index-Breast Cancer Association. Cancer Epidemiol Biomarkers Prev 25:105–113PubMedCrossRef

196.

Schernhammer ES, Sperati F, Razavi P et al (2013) Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. Breast Cancer Res 15:R46PubMedPubMedCentralCrossRef

197.

Sergentanis TN, Diamantaras AA, Perlepe C et al (2014) IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update 20:106–123PubMedCrossRef

198.

Shi LF, Wu Y, Li CY (2016) Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis. Menopause 23:417–424PubMed

199.

Shim SH, Lee SJ, Kim SN (2014) Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 50:1628–1637PubMedCrossRef

200.

Shufelt CL, Braunstein GD (2008) Testosterone and the breast. Menopause Int 14:117–122PubMed

201.

Shushan A, Paltiel O, Iscovich J et al (1996) Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 65:13–18PubMedCrossRef

202.

Siristatidis C, Sergentanis TN, Kanavidis P et al (2013) Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer – a systematic review and meta-analysis. Hum Reprod Update 19:105–123PubMedCrossRef

203.

Smith JS, Green J, Berrington De Gonzalez A et al (2003) Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361:1159–1167PubMedCrossRef

204.

Soerjomataram I, Coebergh JW, Louwman MW et al (2007) Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands? J Clin Oncol 25:5038–5039 (author reply 5039–5040)PubMedCrossRef

205.

Soini T, Hurskainen R, Grenman S et al (2016) Levonorgestrel-releasing intrauterine system and the risk of breast cancer: a nationwide cohort study. Acta Oncol (Madr) 55:188–192CrossRef

206.

Stanczyk FZ, Hapgood JP, Winer S et al (2013) Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 34:171–208PubMedCrossRef

207.

Sturdee DW (2013) Are progestins really necessary as part of a combined HRT regimen? Climacteric 16(Suppl 1):79–84PubMedCrossRef

208.

Sulaica E, Han T, Wang W et al (2016) Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat 157:203–210PubMedCrossRef

209.

Tamimi RM, Byrne C, Colditz GA et al (2007) Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 99:1178–1187PubMedCrossRef

210.

Thomas CC, Wingo PA, Dolan MS et al (2009) Endometrial cancer risk among younger, overweight women. Obstet Gynecol 114:22–27PubMedCrossRef

211.

Trabert B, Wentzensen N, Yang HP et al (2012) Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study. Br J Cancer 107:1181–1187PubMedPubMedCentralCrossRef

212.

Trapido EJ (1981) A prospective cohort study of oral contraceptives and breast cancer. J Natl Cancer Inst 67:1011–1015PubMed

213.

Trinkaus M, Chin S, Wolfman W et al (2008) Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 13:222–231PubMedCrossRef

214.

Tsilidis KK, Allen NE, Key TJ et al (2011) Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control 22:1075–1084PubMedCrossRef

215.

Tsilidis KK, Allen NE, Key TJ et al (2011) Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 105:1436–1442PubMedPubMedCentralCrossRef

216.

Ursic-Vrscaj M, Bebar S, Zakelj MP (2001) Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 8:70–75PubMedCrossRef

217.

Vaccarella S, Herrero R, Dai M et al (2006) Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 15:2148–2153PubMedCrossRef

218.

Varma R, Soneja H, Bhatia K et al (2008) The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia – a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 139:169–175PubMedCrossRef

219.

Venn A, Watson L, Bruinsma F et al (1999) Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 354:1586–1590PubMedCrossRef

220.

Verkooijen HM, Koot VC, Fioretta G et al (2008) Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 107:389–395PubMedCrossRef

221.

Von Euler-Chelpin M (2011) Breast cancer incidence and use of hormone therapy in Denmark 1978–2007. Cancer Causes Control 22:181–187CrossRef

222.

Walker K, Bratton DJ, Frost C (2011) Premenopausal endogenous oestrogen levels and breast cancer risk: a meta-analysis. Br J Cancer 105:1451–1457PubMedPubMedCentralCrossRef

223.

Wan YL, Holland C (2011) The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review. Climacteric 14:622–632PubMedCrossRef

224.

Wang J, Yang DL, Chen ZZ et al (2016) Associations of body mass index with cancer incidence among populations, genders, and menopausal status: a systematic review and meta-analysis. Cancer Epidemiol 42:1–8PubMedCrossRef

225.

Wartko P, Sherman ME, Yang HP et al (2013) Recent changes in endometrial cancer trends among menopausal-age U.S. women. Cancer Epidemiol 37:374–377PubMedPubMedCentralCrossRef

226.

Weedon-Fekjaer H, Bakken K, Vatten LJ et al (2012) Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. BMJ 344:e299PubMedPubMedCentralCrossRef

227.

Weiderpass E, Adami HO, Baron JA et al (1999) Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91:1131–1137PubMedCrossRef

228.

Yang HP, Trabert B, Murphy MA et al (2012) Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer 131:938–948PubMedCrossRef

229.

Yang HP, Anderson WF, Rosenberg PS et al (2013) Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States. J Clin Oncol 31:2146–2151PubMedPubMedCentralCrossRef

230.

Yang TY, Cairns BJ, Allen N et al (2012) Postmenopausal endometrial cancer risk and body size in early life and middle age: prospective cohort study. Br J Cancer 107:169–175PubMedPubMedCentralCrossRef

231.

Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103:250–263PubMedCrossRef

232.

Ye J, Jia J, Dong S et al (2014) Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev 23:158–165PubMedCrossRef

233.

Zeng F, Shi J, Long Y et al (2015) Adiponectin and endometrial cancer: a systematic review and meta-analysis. Cell Physiol Biochem 36:1670–1678PubMedCrossRef

234.

Zhao J, Li Y, Zhang Q et al (2015) Does ovarian stimulation for IVF increase gynaecological cancer risk? A systematic review and meta-analysis. Reprod Biomed Online 31:20–29PubMedCrossRef

235.

Zhou B, Sun Q, Cong R et al (2008) Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 108:641–651PubMedCrossRef

236.

Zreik TG, Mazloom A, Chen Y et al (2010) Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat 124:13–26PubMedCrossRef

Titel: Hormones and risk of breast and gynecological cancer
A systematic review
verfasst von: Dr. med. Susanne Schüler-Toprak
Stephan Seitz
Olaf Ortmann
Publikationsdatum: 10.01.2017
Verlag: Springer Medizin
Schlagwörter: Gynäkologische Onkologie
Kontrazeption
Hormonsubstitution
Mammakarzinom
Erschienen in: Die Gynäkologie / Ausgabe 1/2017
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI: https://doi.org/10.1007/s00129-016-4004-0

Passend zum Thema

Bei Immuntherapien das erhöhte Thromboserisiko beachten

Unter modernen Systemtherapien versechsfacht sich das VTE-Risiko. Warum diese Daten relevant für die Behandlung krebsassoziierter Thrombosen sind, erläutert Prof. F. Langer im Interview. So kann es durch Immuntherapien zu inflammatorischen Syndromen z.B. im GI-Trakt kommen. Nebenwirkungen wie Durchfall oder Mukositis haben dann Einfluss auf die Wirksamkeit oraler Antikoagulantien. Aber auch in punkto Blutungsrisiko ist Vorsicht geboten. Wann hier bevorzugt NMH eingesetzt werden sollten, erläutert Prof. Langer im Interview.

CAT-Management ist ganz einfach – oder doch nicht?

Krebsassoziierte venöse Thromboembolien (CAT) haben in den vergangenen Jahren stetig zugenommen. Was hat der Anstieg mit modernen Antitumortherapien zu tun? Venöse Thromboembolien sind relevante Morbiditäts- und Mortalitätsfaktoren in der Onkologie. Besonders hoch sind die Risiken bei Tumoren des Abdominalraums. Eine antithrombotische Primärprophylaxe ist daher gerade bei gastrointestinalen (GI-) Tumoren auch im ambulanten Setting wichtig.

Management von Thromboembolien bei Krebspatienten

Die Thromboembolie ist neben Infektionen die zweithäufigste Todesursache bei Krebspatienten. Die Behandlung der CAT (cancer associated thrombosis) ist komplex und orientiert sich am individuellen Patienten. Angesichts einer Vielzahl zur Verfügung stehender medikamentöser Behandlungsoptionen finden Sie hier Video-Experteninterviews, Sonderpublikationen und aktuelle Behandlungsalgorithmen zur Therapieentscheidung auf Basis von Expertenempfehlungen.

Passend zum Thema

AGO-Leitlinie 2024: Update zu CDK4 & 6 Inhibitoren

Die Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) hat am 02. März 2024 ihre aktualisierten Empfehlungen präsentiert.[1,2] Welchen Stellenwert CDK4 & 6 Inhibitoren in der Therapie des Hormonrezeptor-positiven (HR+), HER2-negativen (HER2-) Mammakarzinoms haben, erfahren Sie hier im Update.

Finale OS-Analyse der MONARCH-3-Studie vorgestellt

In der MONARCH-3-Studie erhielten Patientinnen mit fortgeschrittenem HR+, HER2- Brustkrebs Abemaciclib [1,a] in Kombination mit nicht-steroidalem Aromatasehemmer (nsAI). Die finalen Daten bestätigen den in früheren Analysen beobachteten Unterschied zugunsten der Kombinationstherapie. [2] Details dazu vom SABCS 2023.

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom

Es erwarten Sie praxisrelevante Patientenfälle, kompakte Studiendarstellungen, informative Experteninterviews sowie weitere spannende Inhalte rund um das HR+, HER2- Mammakarzinom.

Weitere Lesetipps

Aktuelle Strategien zur Systemtherapie des frühen Mammakarzinoms

CAT-Management - Was gibt es Neues bei den NMH

CAT: Was tun bei Lücken in der Evidenz

Sichere Antikoagulation bei ständig wechselnden Risikokonstellationen

"Warum ich?" Aktuelle Erkenntnisse zur Frage aller Fragen bei Krebs

S3-Leitlinie Lungenkarzinom soll mit Fortschritt mithalten

Bildnachweise

Bei Immuntherapien das erhöhte Thromboserisiko beachten /© Leo Pharma GmbH, CAT-Management ist ganz einfach – oder doch nicht?/© LEO Pharma GmbH, Thrombus und Patientin im Gespräch/© crevis / adobe.stock.com (Symbolbild mit Fotomodell), Brustkrebsschleife auf rosa-pinkem Hintergrund/© filo | iStock, Pfeil auf Zielscheibe/© Kunakorn Rassadornyindee | iStock, Schematische Darstellung der weiblichen Brust/© iStock.com | peterschreiber.media, Prof Klamroth/© Leo Pharma GmbH, Krankenhauspharmazie/© Leo Pharma GmbH, Interview Prof. Beyer Westendorf/© LEO Pharma, CAT-Management - Was gibt es Neues bei den NMH/© Leo Pharma GmbH, CAT: Was tun bei Lücken in der Evidenz/© Leo Pharma GmbH, c/© LEO Pharma GmbH, Adenokarzinom des Magens/© jxfzsy / Getty Images / iStock, Digitale Mammographien links in kraniokaudaler Projektion./© Weigel, S. et al. / all rights reserved Springer Medizin Verlag GmbH, Frau mit Kopftuch und Infusion/© FatCamera / Getty Images / iStock (Symbolbild mit Fotomodell), Endoskopisches Bild eines Kolonkarzinoms/© Mehdorn M et al. / all rights reserved Springer Medizin Verlag GmbH, Brustbestrahlung/© Lange T et al. / all rights reserved Springer Medizin Verlag GmbH, Prostatakarzinom/© Kateryna_Kon / stock.adobe.com, Ekzem an der Brustwarze/© T. Jansen, NSCLC Adenokarzinom mit EGFR-Mutation und TTF-1-Positivität/© Tapia, C. et al. / all rights reserved Springer Medizin Verlag GmbH, Ältere Frau schluckt Tablette/© David Pereiras / stock.adobe.com (Symbolbild mit Fotomodellen), Patientin schaut besorgt auf Infusionsbeutel/© KatarzynaBialasiewicz / Getty Images / iStock (Symbolbild mit Fotomodellen), Ältere Frau im Gespräch mit ihrer Ärztin/© pucko_ns / stock.adobe.com (Symbolbild mit Fotomodell), Frau mit Kopftuch sitzt auf Krankenhausbett/© (M) LIGHTFIELD STUDIOS / stock.adobe.com (Symbolbild mit Fotomodell), Zeichen einer Rechtsherzbelastung bei Lungenembolie/© Hobohm L, et al. / all rights reserved Springer Medizin Verlag GmbH, Pflanzliches Arzneimittel/© Chariclo / Fotolia, Drei Patienten mit idealen Befunden für Salvage-Lymphadenektomie./© Horn, T. et al. / all rights reserved Springer Medizin Verlag GmbH, CT: fulminante Lungenarterienembolie/© Staab B et al. / all rights reserved Springer Medizin Verlag GmbH, Arzt zeigt Patient eine Grafik auf dem Tablet/© Pixel-Shot / stock.adobe.com (Symbolbild mit Fotomodellen), Ärztin kontrolliert Infusionssystem/© Wasan / stock.adobe.com (Symbolbild mit Fotomodell), Radiochirurgie: Hirnmetastase eines nichtkleinzelligen Lungenkarzinoms frontal rechts/© Diehl, C., Combs, S.E. / all rights reserved Springer Medizin Verlag GmbH, Ältere Frau mit Tabletten in der Hand/© LIGHTFIELD STUDIOS / stock.adobe.com (Symbolbild mit Fotomodell), Supralevatorischer Abszess in der Computertomographie/© Ommer A et al. / all rights reserved Springer Medizin Verlag GmbH, Lokal fortgeschrittenes Prostatakarzinom/© Preisser & Tilki / all rights reserved Springer Medizin Verlag GmbH, Immunhistochemische Analytik am Beispiel eines kolorektalen Karzinoms./© Büttner, R., Friedrichs, N. / all rights reserved Springer Medizin Verlag GmbH, Scharf begrenzte landkartenartige erythematöse Plaques/© M. Birke et al. / all rights reserved Springer Medizin Verlag GmbH, Postradiogene Morphea/© Stephan R. Künzel und Claudia Günther / all rights reserved Springer Medizin Verlag GmbH, Blutabnahme/© Grafvision / stock.adobe.com (Symbolbild mit Fotomodell), Arzt hält Koloskop/© Graphicroyalty / stock.adobe.com (Symbolbild mit Fotomodell), Metastasierendes nicht-kleinzelliges Lungenkarzinom/© Urushibara M. et al. doi.org/10.1186/s12957-023-02920-2 unter CC-BY 4.0, Infusion/© pix4U / Stock.adobe.com (Symbolbild mit Fotomodell), Operation bei Blasenkrebs/© anistidesign / Fotolia, Ärztin klärt Patientin über Medikamente auf/© auremar / Fotolia (Symbolbild mit Fotomodellen), Beckenvenenthrombose/© Jung et al. / all rights reserved Springer Medizin Verlag GmbH, Short-Segment-Barrett-Ösophagus mit submukosalem Adenokarzinom/© Baumer, S., Pech, O. / all rights reserved Springer Medizin Verlag GmbH, Therapieresistente Brustkrebszellen (in Rot)/© Sheheryar Kabraji und Sridhar Ramaswamy/NCI/cancer.gov, Periphere ulzerative Keratitis (PUK)/© Springer Medizin Verlag GmbH, Ärztin informiert ältere Patientin/© pucko_ns / stock.adobe.com (Symbolbild mit Fotomodellen), Klinisches Bild der Angiosarkome/© Beispiel: Musterfrau M et al. / all rights reserved Springer Medizin Verlag GmbH, Bestrahlungsplan bei Rektumkarzinom/© Springer Medizin Verlag GmbH, Histologische Befunde in der HE-Färbung (a) und PAS-Färbung (b)/© Brommer M. et al. / all rights reserved Springer Medizin Verlag GmbH, Molekulargenetische Testung bei Krebserkrankungen/© Max Kratzer, Intensivstation/© beerkoff / Fotolia (Symbolbild mit Fotomodellen), Person setzt DNS-Probe in Maschine ein/© Vit Kovalcik / stock.adobe.com (Symbolbild mit Fotomodell), Frau erhält Infusion/© Seventyfour / stock.adobe.com (Symbolbild mit Fotomodell), Mit dem MIBI(Multiplexed ion beam imaging)-Mikroskop aufgenommenes kolorektales Karzinom/© Mayer, A., Haist, M. / all rights reserved Springer Medizin Verlag GmbH, Darmpolyp/© Springer Medizin Verlag GmbH, Rektumfrühkarzinom/© SM Hürtgen, JJW. Tischendorf, Stanzbiopsie bei Mammakarzinom/© Kuehnle E et al. / all rights reserved Springer Medizin Verlag GmbH

Springer Medizin

Abstract

Background

Objective

Material and methods

Results and conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Integrative Medizin in der gynäkologischen Onkologie

Magazin

CME: Weibliche Sexualität und sexuelle Störungen

Integrative Medizin – Anwendung bei Nebenwirkungen

Update Gynäkologie

Gutachterkommission Nordrhein mit neuem Statut

Passend zum Thema

Passend zum Thema

Weitere Lesetipps